Session » Health Services Research – ACR/ARP Poster I

Date: Saturday, November 16, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 0203

Agreement of Administrative Pharmacy Dispensing with Patient-Reported Use of Oral Glucocorticoids in a Rheumatoid Arthritis Cohort

10:30AM-12:30PM: Abstract Number: 0215

BP Connect Improves Follow-up of High Blood Pressure in Urban Rheumatology and Non-Rheumatology Clinics

10:30AM-12:30PM: Abstract Number: 0216

Can Immune Checkpoint Inhibitors Safely Combat Cancer in Patients with Rheumatoid Arthritis?

10:30AM-12:30PM: Abstract Number: 0205

Cardiovascular Event Risks Among Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0211

Characteristics of Hospitalizations and Outpatient Follow-up for Patients with SLE at an Academic Hospital Setting in Austin, Texas

10:30AM-12:30PM: Abstract Number: 0209

Characteristics of Ordering Providers and Patients with Positive Antinuclear Antibodies: A Pragmatic, Risk Model Study

10:30AM-12:30PM: Abstract Number: 0212

Costs of Hospitalization in Patients with SLE: An Analysis of the National Inpatient Sample

10:30AM-12:30PM: Abstract Number: 0198

COVID-19 Vaccination and Hospitalization Rates Differ Between People with Diagnosed Immune Mediated Inflammatory Disease and the General Population: A Population-based Study

10:30AM-12:30PM: Abstract Number: 0199

Delivery of Guideline Concordant Care in Childhood-Onset Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 0213

Electronic Medical Record Inbox Volume Association with Physician Gender, Physician Burnout, and the COVID-19 Pandemic at an Academic Rheumatology Center

10:30AM-12:30PM: Abstract Number: 0200

Evaluating the Effectiveness of Educational Initiatives on Recruiting Underrepresented Participants into SLE Clinical Trials

10:30AM-12:30PM: Abstract Number: 0207

Investigation of Delays in Cancer Screening in RA

10:30AM-12:30PM: Abstract Number: 0204

Making Rheum for Palliative Care in Rheumatology: Perspectives of Rheumatology and Palliative Care Clinicians

10:30AM-12:30PM: Abstract Number: 0214

Real-World Treatment Patterns of Clinical Practice Guideline Therapies in Rheumatoid Arthritis-Associated Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 0210

Rheumatology, Heal Thyself: The Experience of Underrepresented Physicians in Rheumatology

10:30AM-12:30PM: Abstract Number: 0202

Survival in Patients with Rheumatoid Arthritis and Early-Stage Colorectal, Lung, or Prostate Cancer Receiving Tumor Necrosis Factor Alpha Inhibitors

10:30AM-12:30PM: Abstract Number: 0217

Understanding Treatment Goals and Factors Influencing Decisions About Clinical Trial Participation in Lupus Patients from Diverse Backgrounds

10:30AM-12:30PM: Abstract Number: 0208

Unlocking COVID-19 Vaccination Choices in Rheumatoid Arthritis: Insights from a Monocentric Study

10:30AM-12:30PM: Abstract Number: 0206

Urate Lowering Therapy to Acute Treatment Ratio (ULTrA) Index – a Novel Quality Indicator Associated with Reduced Hospital Admissions for Gout

10:30AM-12:30PM: Abstract Number: 0201

Use of Infrared Thermography for Expedited Rheumatology Referral in a Primary Care Center

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].